Pseudomembranous colitis following bortezomib therapy in a myeloma patient.
The proteasome inhibitor, bortezomib, has antimyeloma activity even in myeloma cells refractory to multiple prior treatments. The most commonly reported adverse events in patients receiving bortezomib are sensory neuropathy, thrombocytopenia and gastrointestinal events. We report a patient with myeloma who developed pseudomembranous colitis after bortezomib treatment. Bortezomib has the boronic acid moiety which improves the specificity of proteasome inhibition and can be used as non-beta-lactam-based beta-lactamase inhibitors. This case indicates that gastrointestinal toxicities by bortezomib may be caused, in part, as a result of change in the colonization of colonic microflora.
Moon
Sung-Jin
SJ
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Min
Chang-Ki
CK
Lee
Dong-Gun
DG
Lee
Seok
S
Lee
Jong-Wook
JW
Min
Woo-Sung
WS
Kim
Chun-Choo
CC
Kim
Myungshin
M
Park
Gyeongsin
G
Kim
Younggu
Y
D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001897:Boronic Acids / Q000009:adverse effects*; D000069286:Bortezomib; D004761:Enterocolitis, Pseudomembranous / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D008795:Metronidazole / Q000627:therapeutic use; D009101:Multiple Myeloma / Q000188:drug therapy*; D011719:Pyrazines / Q000009:adverse effects*
D000900:Anti-Bacterial Agents; D000970:Antineoplastic Agents; D001897:Boronic Acids; D011719:Pyrazines; D008795:Metronidazole; D000069286:Bortezomib